coronavirus
rna
virus
usual
caus
mild
upper
respiratori
ill
emerg
sar
sever
acut
respiratori
syndrom
mer
middl
east
respiratori
syndrom
focuss
global
attent
clinic
signific
cornavirus
current
middl
east
respiratori
syndrom
novel
coronaviru
merscov
first
isol
june
respiratori
tract
businessman
bisha
area
saudi
arabia
subsequ
die
pneumonia
renal
failur
juli
merscov
caus
laboratori
confirm
case
death
repres
high
case
fatal
rate
high
case
fatal
rate
like
relat
pattern
diseas
probabl
see
tip
iceberg
critic
ill
admit
patient
high
fatal
rate
like
declin
milder
clinic
case
emerg
similar
sar
common
symptom
patient
merscov
includ
fever
cough
short
breath
gastrointestin
symptom
patient
pneumonia
major
report
multipl
comorbid
condit
rapid
deploy
effect
therapeut
high
prioriti
current
specif
therapi
vaccin
merscov
clinic
experi
sar
suggest
number
intervent
includ
ribavirin
without
corticosteroid
interferon
alfa
corticosteroid
ribavirin
lopinavir
ritonavir
convalesc
plasma
may
improv
outcom
patient
data
conclus
purpos
review
first
summar
effect
treatment
attempt
identifi
therapeut
approach
could
help
select
appropri
therapeut
option
patient
merscov
infect
middl
east
respiratori
syndrom
coronaviru
merscov
detect
number
countri
middl
east
europ
appar
high
mortal
rate
phylogenet
relat
sar
coronaviru
also
associ
sever
respiratori
ill
well
nosocomi
transmiss
healthcar
set
current
intern
recommend
support
specif
therapi
howev
number
agent
use
sar
epidem
possibl
might
activ
relat
mer
coronaviru
review
literatur
safeti
efficaci
therapi
use
patient
sar
view
potenti
use
patient
merscov
infect
intern
societi
infecti
diseas
publish
elsevi
ltd
right
reserv
inconclus
mention
total
number
respond
rather
surpris
patient
long
treatment
delay
good
respons
partli
relat
alloc
differ
regimen
random
criteria
describ
paper
paramet
influenc
treatment
respons
time
symptom
onset
treatment
day
time
admiss
treatment
day
time
maxim
radiograph
score
treatment
day
maxim
radiograph
score
maxim
radiograph
score
p
case
seri
agent
includ
ribavirin
interferon
lopinavir
ritonavir
lpvr
convalesc
plasma
exclud
corticosteroid
studi
beyond
scope
review
manag
sever
pneumonia
well
cover
guidelin
data
extract
public
includ
author
name
public
year
type
studi
level
evid
sampl
size
intervent
dose
durat
indic
rout
time
administr
number
patient
efficaci
safeti
outcom
intervent
outcom
interest
includ
mortal
rate
measur
morbid
advers
effect
outcom
report
select
studi
includ
death
mechan
ventil
improv
symptom
admiss
intens
care
unit
infecti
complic
success
discharg
advers
effect
clinic
studi
critic
apprais
aspect
assess
includ
studi
design
possibl
bia
select
control
group
treatment
alloc
whether
treatment
regimen
report
outcom
consist
studi
tabul
summar
narr
way
group
treatment
strategi
categor
articl
depend
drug
use
tabul
result
type
studi
dose
durat
time
administr
indic
medic
number
patient
includ
studi
plu
final
outcom
studi
score
use
us
prevent
servic
task
forc
score
system
level
evid
loe
evid
obtain
least
one
properli
design
random
control
trial
level
evid
obtain
welldesign
control
trial
without
random
level
evid
obtain
welldesign
cohort
casecontrol
analyt
studi
prefer
one
center
research
group
level
evid
obtain
multipl
time
seri
without
intervent
dramat
result
uncontrol
trial
might
also
regard
type
evid
level
iii
opinion
respect
author
base
clinic
experi
descript
studi
report
expert
committe
identifi
studi
sar
coronaviru
includ
studi
exclud
studi
sinc
vitro
studi
corticosteroid
studi
nontherapeut
studi
overal
analyz
studi
nine
use
ribavirin
alon
interferon
tabl
two
use
lopinavir
ritonavir
tabl
six
use
convalesc
plasma
tabl
one
studi
interferon
alpha
tabl
one
studi
compar
interferon
alpha
versu
ribavirin
summari
differ
studi
present
tabl
lot
concern
worldwid
emerg
merscov
although
infect
control
molecular
diagnost
intern
public
health
improv
consider
sinc
sar
epidem
still
proven
licens
therapi
coronaviru
infect
high
mortal
associ
merscov
led
us
conduct
systemat
review
summar
avail
option
treatment
novel
coronaviru
infect
base
previou
report
therapi
sar
relat
coronaviru
commonli
use
agent
broad
spectrum
antivir
ribavirin
seven
report
use
ribavirin
sar
patient
although
four
report
control
group
mortal
benefit
inconsist
mortal
rate
two
studi
show
improv
symptom
patient
icu
admiss
rate
major
problem
ribavirin
signific
incid
advers
event
especi
hemolysi
report
time
start
antivir
agent
import
viru
infect
one
studi
compar
oseltamivir
versu
ribavirin
show
obviou
respons
ribavirin
howev
treatment
start
day
symptom
might
led
poorer
outcom
one
random
control
trial
compar
ribavirin
versu
show
advantag
ribavirin
interferon
patient
sar
addit
observ
studi
compar
untreat
control
interferon
led
improv
clinic
laboratori
paramet
compar
control
patient
howev
standard
regim
use
advers
event
well
document
addit
lopinavirritonavir
ribavirin
regimen
associ
improv
clinic
outcom
reduc
death
rate
compar
ribavirin
regimen
alon
observ
studi
studi
detail
tabl
studi
address
effect
convalesc
plasma
studi
mainli
case
report
limit
generaliz
find
three
studi
sar
patient
patient
interferon
treatment
group
shorter
time
resolut
lung
radiograph
abnorm
p
better
oxygen
satur
p
resolv
need
supplement
oxygen
rapidli
p
less
increas
creatin
kinas
level
p
show
trend
toward
rapid
resolut
lactat
dehydrogenas
level
compar
group
receiv
corticosteroid
alon
inconclus
mechan
ventil
lower
mortal
compar
group
versu
intriguingli
vitro
studi
show
convalesc
plasma
sar
patient
might
contain
crossreact
antibodi
betacoronaviru
includ
merscov
sera
antibodi
antimerscov
neutral
antibodi
low
titer
convalesc
sera
recommend
recent
studi
intern
sever
acut
respiratori
emerg
infect
consortium
isar
crossreact
antibodi
may
present
convalesc
plasma
sar
patient
betacoronaviru
may
associ
better
outcom
reduc
mortal
shorter
hospit
stay
consider
technic
hurdl
overcom
convalesc
sera
wide
recommend
therapeut
agent
modern
era
current
need
establish
serolog
test
diagnos
patient
mild
diseas
thu
identifi
patient
possibl
donor
convalesc
sera
conclud
use
ribavirin
may
improv
outcom
reduc
mortal
shown
number
studi
one
reason
failur
ribavirin
report
may
time
use
ribavirin
day
symptom
compar
studi
show
benefit
ribavirin
start
within
hour
hospit
diagnosi
sar
establish
major
limit
ribavarin
signific
toxic
dose
use
treat
patient
sar
although
addit
lopinavirritonavir
ribavirin
appear
better
outcom
patient
sar
report
lopinavirritonavir
activ
vitro
merscov
vitro
studi
fail
yield
potent
therapeut
agent
despit
search
includ
inhibitor
among
limit
review
heterogen
review
studi
term
wide
rang
treatment
dosag
frequenc
rout
administr
durat
time
administr
report
treatment
effect
interpret
caution
due
lack
random
control
trial
also
drawn
sar
literatur
sar
close
relat
viru
clearli
differ
sar
merscov
data
might
abl
directli
extrapol
merscov
infect
patient
use
discuss
agent
would
requir
monitor
hematolog
biochem
paramet
treatment
detect
prevent
advers
effect
associ
therapi
possibl
dosag
discuss
agent
especi
unavail
intraven
ribavarin
list
tabl
tabl
also
includ
possibl
dosag
pegel
interferona
pegifna
commonli
use
treatment
hepat
c
viru
infect
pegifna
time
effect
vitro
merscov
sarscov
long
halflif
pegifna
associ
advers
effect
call
extra
attent
use
shorteract
interferon
use
interferon
therapi
ribavirin
recommend
patient
hepat
c
viru
infect
renal
dysfunct
clcr
mlminut
emerg
merscov
lack
high
qualiti
clinic
evid
support
recommend
use
avail
therapeut
option
clear
need
develop
protocol
use
randomizedcontrol
trial
order
determin
effect
therapi
novel
emerg
pathogen
